Brought to you by 
Centocor teams up with Molecular Partners
21 Jul 2015
Executive Summary
Molecular Partners AG (spun off from the University of Zurich in 2004) has agreed to use its DARPin(Designed Ankyrin Repeat Proteins) technology to identify two inflammatory disease targets provided by J&J's Centocor Research & Development unit.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Centocor teams up with Molecular Partners
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice